BioLineRx To Present Pre-Clinical Data Demonstrating Strong Synergy Between GLIX1 And Various PARP Inhibitors In HR-Proficient Ovarian Cancer Cell Lines At The 2026 European Society For Medical Oncology Annual Meeting In October
Benzinga Newsdesk 3 months ago
News
Presentation Details:Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell LinesPresentation #: 1435ePPresentation type: e-PosterLocation: e-Poster
Presentation Details:
Title: GLIX1, a TET2 Activator Targeting the DNA Damage Response, Synergizes with PARP Inhibitors in Ovarian Cancer Cell Lines
Presentation #: 1435eP
Presentation type: e-Poster
Location: e-Poster Area, Hall 25